ストックスクリーナーアプリを入手
5.93
1.02%
0.06
前日終値:
$5.87
開ける：
$5.97
24時間の取引高:
35,048
Relative Volume:
0.39
時価総額：
$99.21M
収益：
-
当期純損益:
$-14.88M
株価収益率:
-6.051
EPS:
-0.98
ネットキャッシュフロー:
$-10.29M
1週間 パフォーマンス:
-1.98%
1か月 パフォーマンス:
+13.60%
6か月 パフォーマンス:
-6.17%
1年 パフォーマンス:
-30.24%
1日の値動き範囲:
$5.90
$6.15
1週間の範囲:
$5.63
$6.4177
52週間の値動き範囲:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
名前
Coya Therapeutics Inc
セクター
電話
650.739.3939
住所
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.93 | 101.19M | 0 | -14.88M | -10.29M | -0.98 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-04 | 開始されました | D. Boral Capital | Buy |
Coya Therapeutics Inc (COYA) 最新ニュース
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Holdings Lifted by Tower Research Capital LLC TRC - Defense World
Coya Therapeutics (COYA): Analyst Maintains Buy Rating and Price - GuruFocus
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
Coya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Coya (COYA) Reports Lower Q1 Revenue Than Expected | COYA Stock News - GuruFocus
Coya Therapeutics (COYA) Reports Q1 EPS and Cash Position - GuruFocus
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Stock Titan
Coya Therapeutics (COYA) Projected to Post Quarterly Earnings on Thursday - Defense World
How To Trade (COYA) - news.stocktradersdaily.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Geode Capital Management LLC - Defense World
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
Breakthrough: New GLP-1/IL-2 Combo Drug Outperforms Standard Therapy by 42% in Alzheimer's Research - Stock Titan
(COYA) Long Term Investment Analysis - news.stocktradersdaily.com
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo
Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia
Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe
GMP Production of Exosomes Slated for Later This Year - streetwisereports.com
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World
Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports
What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance
Coya Therapeutics Inc (COYA) 財務データ
収益
当期純利益
現金流量
EPS
Coya Therapeutics Inc (COYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):